Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Nephros stock

Learn how to easily invest in Nephros stock.

Nephros Inc
+ $0.06 ( + 4.08%)

Nephros Inc is a medical instruments & supplies business based in the US. Nephros shares (NEPH) are listed on the NASDAQ and all prices are listed in US Dollars. Nephros employs 34 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Nephros

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NEPH – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Nephros stock price (NASDAQ: NEPH)

Use our graph to track the performance of NEPH stocks over time.

Nephros shares at a glance

Information last updated 2022-06-25.
Latest market close$1.47
52-week range$1.51 - $11.67
50-day moving average $2.56
200-day moving average $5.32
Wall St. target price$7.63
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.55

Buy Nephros shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
Stocks, ETFs, Cryptocurrency
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Axos Bank Self Directed Investing
when you open an account and deposit at least $1500.
Vanguard Personal Advisor
Stocks, Mutual funds, ETFs
Financial advice powered by relationships, not commissions.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Nephros stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Nephros price performance over time

Historical closes compared with the close of $1.47 from 2022-06-29

1 week (2022-06-24) -4.55%
1 month (2022-06-01) -20.11%
3 months (2022-03-28) N/A
6 months (2021-12-31) -75.08%
1 year (2021-07-01) -85.31%
2 years (2020-07-01) -81.78%
3 years (2019-07-01) 145.00%
5 years (2017-06-29) 535.81%

Nephros financials

Revenue TTM $9.9 million
Gross profit TTM $5.7 million
Return on assets TTM -19.69%
Return on equity TTM -36.61%
Profit margin -56.22%
Book value $0.99
Market capitalisation $15.9 million

TTM: trailing 12 months

Nephros share dividends

We're not expecting Nephros to pay a dividend over the next 12 months.

Have Nephros's shares ever split?

Nephros's shares were split on a 1:9 basis on 9 July 2019. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Nephros shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Nephros shares which in turn could have impacted Nephros's share price.

Nephros share price volatility

Over the last 12 months, Nephros's shares have ranged in value from as little as $1.51 up to $11.67. A popular way to gauge a stock's volatility is its "beta".

NEPH.US volatility(beta: 1.27)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nephros's is 1.2731. This would suggest that Nephros's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Nephros overview

Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

Frequently asked questions

What percentage of Nephros is owned by insiders or institutions?
Currently 10.147% of Nephros shares are held by insiders and 46.895% by institutions.
How many people work for Nephros?
Latest data suggests 34 work at Nephros.
When does the fiscal year end for Nephros?
Nephros's fiscal year ends in December.
Where is Nephros based?
Nephros's address is: 380 Lackawanna Place, South Orange, NJ, United States, 07079
What is Nephros's ISIN number?
Nephros's international securities identification number is: US6406714005
What is Nephros's CUSIP number?
Nephros's Committee on Uniform Securities Identification Procedures number is: 640671103

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site